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PREFACE
The main body of this thesis in Chapter III is a journal article titled “In vitro evaluation of loaded
chitosan membranes for pain relief and infection prevention.” This manuscript is to be submitted
to Frontiers in Microbiology.
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ABSTRACT
Wounds resulting from musculoskeletal trauma cause pain and often infection of
damaged tissue. Up to 80% of these infections are due to biofilm formation on wounded tissue.
Bacteria within a biofilm can withstand 1000x the minimum inhibitory concentration of
antibiotics, demonstrating the need for new therapeutics to prevent and treat these infections.
Cis-2-decenoic acid (C2DA) disperses biofilms and can prevent biofilm formation of many
microorganisms. Additionally, local anesthetics like bupivacaine have antimicrobial effects
against bacteria. This study sought to evaluate modified electrospun chitosan membranes as
wound dressings that release C2DA and bupivacaine to prevent infection and alleviate pain
associated with wounds. Release profiles of therapeutics were evaluated, with results indicating
that membranes release active concentrations of both therapeutics for 72 hours. Though higher
concentrations of bupivacaine were not cytocompatible with fibroblasts, membranes were
effective in preventing Methicillin-resistant Staphylococcus aureus biofilm growth in vitro.
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CHAPTER I
INTRODUCTION
Statement of Clinical Problem
There is a growing demand for local delivery systems to treat and prevent infection and
pain during wound healing. These wounds may result from a surgical procedure or implantation
of a medical device, or from other musculoskeletal trauma such as burns. Implantation of
medical devices accounts for approximately 2 million healthcare-associated infections annually
and can only be effectively treated with removal of the implant and aggressive debridement of
surrounding tissue, resulting in significant pain and trauma for patients [1; 2]. Similarly, burn
wounds are incredibly susceptible to infection, with approximately 51% of burn victim deaths
resulting from wound infection [3]. Formation of antibiotic-resistant biofilm, as well as an
alarming rise in multidrug-resistant bacterial strains due to antibiotic overuse, limit the
availability of antimicrobials practical for broad-spectrum antibiotic administration to prevent
and treat wound infections [4; 5]. Therefore, establishing coverage and reducing pain during
early wound management are necessary to effectively reduce both patient costs and trauma.
Bacteria typically colonize wounds by forming a biofilm within 24-72 hours post-injury
[6; 7]; therefore, protection of the wound for this window is critical. These biofilm infections,
caused by microbial communities adhering to the surfaces of implanted devices, surrounding
tissue, and musculoskeletal wounds, are particularly difficult to treat due to their antibiotic
resistance. Bacterial attachment is often accompanied by the secretion of a complex, sugary
structure termed extracellular polymeric substance (EPS), which functions to protect and encase
the community of bacteria in a cohesive polymer matrix [8]. The resulting biofilm is
characterized by increased mechanical stability due to the cohesivity of bacteria within the EPS,
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and significant interconnection and immobilization of the bacterial cells within it. These
immobilized subgroups of bacterial cells within the biofilm, called persister cells, are dormant,
non-dividing cells that are resistant to antibiotics [9]. Because many antibiotics only have
activity in metabolically active or dividing cells, the presence of dormant persister cells often
increases the minimum inhibitory concentration of antibiotics up to 1000 times in biofilm
compared to planktonic bacteria, and also makes them resistant to immune cell clearance [10].
Developing biofilm maintains equilibrium through growth and dispersal. Diffusible
signal factors (DSF) are fatty acid analogs secreted by bacteria to function in a cell-cell
communication mechanism, called quorum sensing [11]. It has been observed that some fatty
acid signaling factors revert persister cells to a metabolically active state, which in combination
with antimicrobials could decrease bacterial viability. These compounds also act to inhibit and
disperse biofilms formed by multiple types of microorganisms, meaning they have crosskingdom efficacy [12]. One well-studied biofilm dispersal signal is cis-2-decenoic acid (C2DA),
which has been shown to inhibit biofilm formation and disperse established biofilms of multiple
strains [13]. In addition to infection prevention, non-opioid pain management strategies such as
delivery of local anesthetics are a top priority for wound treatment, especially as the opioid crisis
reaches epidemic proportions [14]. Studies have also confirmed that in addition to analgesic
effects, local anesthetics such as lidocaine, ropivacaine, and bupivacaine have inherent
antimicrobial effects [15].
Preventative anti-infective strategies in current practice include the local delivery of
therapeutics, anti-biofilm coatings on surfaces and precautionary hygienic measures. However,
additional strategies are required to improve efficacy of these treatments. Moreover, treatments
for existing biofilms are particularly challenging. An established biofilm is often able to survive
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aggressive physio-chemical treatments including UV light, heavy metals, acidity, changes in
hydration or salinity, and phagocytosis [16; 17; 18; 19; 20]. Currently, antimicrobial therapies
have limited efficacy in cases of preformed biofilms such as implant associated osteomyelitis,
blood stream infections, chronic pulmonary infections, dental caries, and endocarditis [21]. Long
term use of antibiotic therapy can help to manage biofilm infections, but often fails while also
increasing the risk of antibiotic resistance and toxic side effects [10]. For instance, Methicillinresistant Staphyloccocus aureus (MRSA) is the cause of more than 50% of all invasive infections
in burn wounds [1]. The occurrence of biofilm infections can lead to increased hospital time and
trauma for patients as well as increased cost of care for hospitalization.
Guided regeneration membranes can provide a covering for healing tissue while also
delivering antimicrobials and local anesthetics for use as wound dressings following injury [22;
23]. Chitosan has been investigated as a sustained drug delivery system due to its
biocompatibility and physiochemical characteristics and is a promising scaffold to deliver
hydrophobic molecules such as C2DA and bupivacaine [24; 25; 26; 27; 28]. Electrospun
chitosan membranes loaded with the local anesthetic bupivacaine and C2DA may serve to 1) act
as a barrier to microbial contamination, 2) release local anesthetics in a controlled manner that
reduce pain and modify the inflammatory response, and 3) release natural, antimicrobial fatty
acids that prevent biofilm contamination. These loaded membranes may be used as wound
dressings for soft tissue wounds following medical device implantation, musculoskeletal trauma,
or burn wounds for prolonged prevention of infection and management of pain.
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Hypothesis and Research Objectives
The innovation of the electrospun chitosan membranes utilized in these wound dressings
is the chemical process for stabilization to maintain the nanofibrous structure in aqueous
environments. In one such modification technique, fatty acid chains are covalently bonded to
chitosan to prevent swelling and dissolution of the membrane fibers [29]. The alkyl groups of the
fatty acids are hypothesized to form a hydrophobic surface on the core chitosan nanofiber, which
may limit aqueous swelling and better retain hydrophobic therapeutics (Figure 1). The
hydrophobic surface minimizes adherence of the fibers to wounded tissue, which in turn
minimizes damage to fragile tissue during dressing changes. Additionally, electrospun
membranes resemble the native fibrous structure of the extracellular matrix to support cell
growth and provide increased surface area for drug delivery.

Figure 1. Schematic of acylated membranes loaded with hydrophobic bupivacaine and C2DA.
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Due to the hydrophobic nature of C2DA, engineering systems for local delivery have
been limited to systems that provide burst release and short duration of release [30]. These
results reinforce the idea that biofilm inhibitors are potential infection prophylactic agents that
promote wound healing, yet highlight the current gap between benchtop findings and useful drug
delivery systems. These modified chitosan wound dressings have significant potential to address
this local delivery gap and to extend the antimicrobial activities of C2DA to up to 72 hours
between dressing changes. Further, the goal for the local anesthetic component is the extended
duration of release through a biomaterial that supports the healing process, allowing for
management of pain and initial inflammatory responses. The following objectives are proposed
to determine the success of this system:
Aim 1: Evaluate release profiles when loading therapeutics in a variety of concentrations.
Hypothesis 1: Bupivacaine and C2DA release can be tailored by loading concentration.
Overall elution goal of 72 hours was selected to match the membrane’s function as a wound
dressing.
Aim 2: Determine antimicrobial activity of bupivacaine, C2DA, and combinations released
from chitosan membranes.
Hypothesis 2: Bupivacaine and C2DA released over the course of 72 hours will have
antimicrobial effects against MRSA.
Aim 3: Determine cellular responses to bupivacaine, C2DA, and combinations released from
chitosan membranes.
Hypothesis 3: Membranes loaded with C2DA and bupivacaine are non-cytotoxic and
promote wound healing responses in fibroblasts.
16

CHAPTER II
LITERATURE REVIEW
Biofilm
Biofilms are the cause of 65-80% of all human infections, and thus remain a significant
problem in the treatment of wounds [31]. Biofilms can form on biotic or abiotic surfaces, be
single or multi-layered, and may contain either homogenous or heterogenous populations of
bacteria [32]. While all biofilms are unique on the basis of their attachment surface and microbial
components, pathogenic biofilms have a number of similarities in the process of their
development and specific phenotypic changes. The analysis of these growth and dispersal
mechanisms have been fundamental in discovering novel therapeutics for the treatment and
prevention of biofilm infections.
The formation of biofilm begins with the attachment of a single planktonic bacterium to a
surface, such as an implanted device or wounded tissue (Figure 2). As microorganisms continue
to aggregate on this surface, they secrete an extracellular polymeric substance (EPS) which is a
complex network of polysaccharides and proteins that facilitate conglomeration of microbes,
assist in bacterial attachment to a surface, and encase bacterial cells to allow the biofilm to
continue growing. Further, the EPS protects the biofilm against the immune response while also
preventing diffusion of antibiotics and other external forces, deeming the biofilm nearly
impenetrable. The forming biofilm reaches full cell density through a unique cell-cell signaling
method, termed quorum sensing. Quorum sensing allows for bacteria within the biofilm to
determine the population density through recognition of secreted signaling molecules, which
they can then use to regulate gene expression as a community [33]. These genetic changes lead
to the development of persister cells, which function as yet another mechanism by which

17

biofilms evade immune cell and antibiotic clearance. Persister cells have a significantly slower
growth rate and while they make up only 1% of the total biofilm population, they survive even
the greatest external stresses and can therefore repopulate the biofilm even following extensive
antimicrobial treatment [9].

Figure 2. Depiction of the biofilm formation and dispersion cycle (reproduced with permission
from © Springer Nature Singapore Pte Ltd. 2019) [34].

Despite their clinical burden, biofilms were not first reported until the 1980s, and were
not reported in wounds until the 1990s [35; 36]. In 1996, Akiyama et al. published the first
article detailing evidence of biofilm in a wound; they found that signs of biofilm formation
began just 3 hours after inoculating a mouse dermal wound with Staphylococcus aureus (S.
aureus) [37]. Similarly, in their 2000 study, Rashid et al. recognized horizontal spread and
systemic infections resulting from Pseudomonas aeruginosa (P. aeruginosa) biofilm in rat burn
wounds [38]. These early studies of biofilm infections within wounds led to further discoveries
throughout the following decades including multi-strain synergy of polymicrobial biofilms and
the ability of biofilm to impair wound healing [36].
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Biofilm in burn wounds
Burns are continuously among the leading causes of injury in the Unites States; in data
published by the Center for Disease Control, 1.1 million burn injuries annually require medical
attention, with 50,000 requiring hospitalization. Biofilm infections can be especially devastating
during treatment of burn wounds, with approximately 51% of burn victim deaths resulting from
complex wound infection [3]. Microorganisms can enter burned dermal tissue through the
patient’s own microflora, or through contact with the environment or healthcare workers [39].
After a burn occurs, the protective mechanisms of the skin (i.e. defensins from keratinocytes and
acidic secretions from sebaceous glands) are severely impaired or lost entirely, allowing
microorganisms to rapidly colonize and form biofilm [40]. While systemic antibiotics are nearly
ineffective in treating biofilm, the reduced blood supply to burned tissue further restricts the
efficacy of typical antibiotic treatment concentrations [39]. Studies have shown that P.
aeruginosa isolates from a burn wound developed EPS within 5 hours of inoculation, and had the
characteristics of a mature biofilm within 10 hours, demonstrating the necessity of taking rapid
preventative measures after a burn occurs [41]. In a clinical study, Moghadam et al. found that
approximately 50% of 135 swabbed burn wounds had been colonized by MRSA, indicating the
prevalence of drug-resistant biofilm formation in burn wounds [42]. Further clinical studies
demonstrated that while debridement of wounds could remove biofilm from wound beds,
biofilms recolonized 2 days after this initial debridement [43]. Each of these studies indicates the
need for prompt and sustained non-antibiotic methods to treat and prevent biofilm in burn
wounds.
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Diffusable signal factors and C2DA
As knowledge regarding the development and spread of biofilm has increased, research
into potential non-antibiotic therapeutics to treat biofilm has simultaneously expanded. One
method in particular is the use of diffusible signal factors (DSF) to both disperse preformed
biofilms and prevent biofilm formation entirely [44]. When a biofilm continues to grow and
mature, bacteria release these intrinsic DSF fatty acids to trigger release from the growth surface
so that bacterial cells can once again become planktonic, travel through the bloodstream, and
recolonize another site as biofilm. Studies have shown that DSF also play a role in modulation of
bacterial antibiotic susceptibility [11]. DSF can be derived naturally from bacterial strains like
Pseudomonas or developed synthetically with slight structural changes that in turn alter their
activity. Because DSF are analogs of natural fatty acids molecules, they have the potential to
impair microbial growth and subsequent biofilm formation while avoiding the consequence of
antibiotic resistance [45].
Considerable investigation into DSF led to the discovery of cis-2-decenoic acid (C2DA)
and its anti-biofilm capabilities by Davies et al. (Figure 3) [13]. C2DA is a medium chain fatty
acid that belongs to a recently defined group of cis-2-alkenoic acids that are known for triggering
communication both within and between different strains of microorganisms [46]. Though its
mechanism of action remains unclear, bacterial signaling through C2DA has been shown to
modulate at least 666 genes, including those involved with chemotaxis, biofilm attachment,
motility, tricarboxylic acid cycle, EPS synthesis, and a number of other pathways essential to
biofilm physiology [13; 47]. C2DA was initially investigated for its ability to inhibit biofilm
formation of P. aeruginosa and disperse established biofilms, but research has since expanded to
determine the efficacy of C2DA against multiple bacterial strains [48]. For example, C2DA has
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been shown to inhibit S. aureus growth and biofilm formation, using concentrations that are not
cytotoxic to fibroblasts [49]. Recent work has begun to indicate that the cis-conformation also
increases membrane permeability and could let more small molecule antibiotics into cells,
making C2DA a potential adjunctive therapy to work synergistically with common antibiotics
[30; 50]. Due to its hydrophobicity and limited solubility, delivery of C2DA has been a
challenge, and often requires the use of ethanol as a carrier. A series of in vitro studies by
Rahmani-Badi et al. confirmed that when combined with antibiotics, C2DA induces dispersal of
both Escherichia coli and Klebsiella pneumoniae biofilms formed on catheters [51]; additionally,
this group reported that C2DA combined with chlorhexidine resulted in removal of dental plaque
formed by Streptococcus mutans and Candida albicans, further proving cross-kingdom efficacy
of C2DA [52].

Figure 3. Chemical structure of cis-2-decenoic acid.

Systems developed to deliver C2DA locally have had variable levels of success, as fatty
acids are often difficult to incorporate into conventional materials for sustained release [53].
Chitosan sponges manufactured with a poly(ethylene glycol) carrier successfully release C2DA
for up to 5 days, depending on loading concentration, though a substantial burst release was seen
during the first day [49]. C2DA and the antibiotic rifampin have been delivered within solid lipid
nanoparticles, and results showed that nanoparticles were more successful as a preventative anti21

biofilm agents compared to free forms of the therapeutics; however, this delivery system was not
capable of eradicating pre-formed biofilm [54]. Furthermore, C2DA was investigated as an antibiofilm coating using phosphatidylcholine as a carrier, and completely inhibited S. aureus on
titanium pins and bone, both with and without antibiotics, in a murine biofilm-based infection
model, though in vitro studies of this coating suggests only a short, burst release of C2DA occurs
[55]. Despite the success of C2DA as a biofilm treatment agent in preliminary studies, the
challenge to develop a successful delivery system remains.
Other systems targeting biofilm
In addition to C2DA, there are a number of other non-antibiotic strategies being studied
for their potential to treat and prevent biofilm infections. Aside from the DSF family of signaling
molecules, bacteria also release fatty acid biosurfactants that similarly play a role in biofilm
formation and dispersion. These includes rhamnolipids, which have anti-adhesive properties that
prevent bacteria from attaching to surfaces and forming biofilm [56]. While lower concentrations
of rhamnolipids increase bacteria cells’ surface hydrophobicity and thus increase their affinity
for other surfaces, higher rhamnolipid concentrations can have the opposite effect and prevent
bacterial attachment [57; 58; 59]. Certain peptides and amino acids may also serve to interrupt
biofilm development through disruption of bacterial cell walls. Studies have shown that both
polyurethane scaffolds and bone grafts loaded with D-amino acids effectively reduce S. aureus
biofilm in vitro and in vivo [60; 61]. Another study combined D-amino acids with antibiotics and
tested them against clinical isolates of P. aeruginosa and S. aureus from deep tissue wounds, and
determined that they are effective in dispersing preformed biofilms and reducing minimum
biofilm inhibitory concentration significantly for rifampin, colistin, and ciprofloxacin [62].
Antimicrobial peptides (AMP) function through a similar mechanism and have been studied
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clinically in additional to in vitro and in vivo models [63; 64; 65]. Some clinical applications
being tested are a topical gel containing the AMP omiganan to treat skin infections, and the AMP
pexiganan to treat infected diabetic foot ulcers [66]. Other applications targeted by AMP systems
include urinary, dental, vaginal, oral, orthopedic, and post-surgical infections, through a variety
of material delivery systems including poly(methyl methacrylate), polyvinyl alcohol, and
calcium phosphate [67; 68; 69; 70; 71; 72; 73; 74; 75; 76].
Enzymes have also been tested due to their potential to target biofilm in early growth
stages by preventing EPS production. Glycoside hydrolase enzymes have been tested with in
vivo wound infection models, with many concluding that while these molecules are functional in
dispersing S. aureus and P. aeruginosa biofilm, they do not eradicate infection unless combined
with antibiotics [77; 78; 79]. Protease enzymes have also shown success in treating biofilm
because of their ability to cleave peptide bonds, which in turn may remove biofilm from its
attached surface [80]. These molecules have proven successful in preventing biofilm formation
for MRSA and Staphylococcus epidermidis both in vitro and in vivo [81; 82; 83]. The
staphylococcal proteolytic enzyme lysostaphin functions by targeting and cleaving bonds within
bacterial cell walls, and is functional in both dispersing and eradicating biofilm of staphylococcal
species [84; 85]. Though not yet commercialized for clinical use, lysostaphin has been tested
with a number of materials including ceramics, polymers, hydrogels, and wound dressings, and
proved capable of reducing infections caused by staphylococcal species [86; 87; 88; 89].
Nanomaterials have also been investigated extensively as a means to deliver therapeutics
for applications as diverse as cancer therapy, neurodegenerative disorders, and ophthalmology
[90; 91; 92; 93]. Because these particles can be reactive, have a large surface area to volume
ratio, and have alterable chemical and physical properties, they are also ideal carriers to deliver
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therapeutics to disrupt biofilm; further, their nanoscopic size allows them to penetrate the EPS
and accumulate within the biofilm to effect growth directly [8; 94; 95]. Polymer-based
nanoparticles have been used to deliver antibiotics though they do not have intrinsic antibacterial
properties; in contrast, metal nanoparticles alone are well-known to be inherently antimicrobial
[95; 96; 97]. Despite cytotoxicity concerns, silver nanoparticles have shown promise as factors to
reduce biofilm formation for both gram-positive and gram-negative bacteria strains, and in skin
wounds [98; 99]. Similarly, zinc oxide particles have been used successfully in wound treatments
in both in vitro and in vivo assessments [100]. Magnetic nanoparticles have been fabricated from
iron oxide and heat up when exposed to magnetic fields to induce local hyperthermia that, when
combined with antibiotics, can successfully eradicate biofilm. These particles have been
modified with other therapeutics including D-amino acids or polymers such as chitosan, chitin,
and polyethylene glycol, which increased biofilm eradication but could result in adverse effects
associated with elevated temperatures [95; 101; 102].
Metabolites have been used as a means to stimulate persister cells within biofilm, so that
they regain susceptibility to aminoglycoside antibiotics. The sugar alcohols mannitol, erythritol,
and fructose combined with antibiotics have shown promise in the treatment of lung, dental, and
wound infections caused by variable strains of bacteria [103; 104; 105]. Most recently, Pace et
al. investigated mannitol delivery from chitosan pastes, and saw reduction in S. aureus biofilm
both in vivo and in vitro [106]. Other anti-biofilm metabolites include Manuka and Ulmo honey,
which have additional antimicrobial properties because they contain hydrogen peroxide, and are
effective against wound pathogens like S. aureus, P. aeruginosa, Enterobacter cloacae, and
Proteus mirabilis, though they were ineffective against Enterococcus faecalis [107; 108; 109].
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Honey has been investigated for delivery through numerous biomaterial systems including
hydrogels, cryogels, and electrospun membranes [110].
Local anesthetics for pain relief
In addition to infection prevention, non-opioid methods to treat pain are currently of great
clinical relevance, especially as the opioid crisis reaches epidemic proportions. Approximately
4% of the adult US population misuses prescription opioids; by 2015 more than 33,000 deaths
were attributed to opioid overdose, with that number increasing to 64,000 in 2017 [111; 112;
113]. Because of the opioid crisis, a number of alternative therapies have been investigated for
the treatment of acute pain associated with post-surgical wounds and musculoskeletal trauma. A
2018 clinical study concluded that low doses of the dissociative anesthetic ketamine provided
comparable effects in pain relief to morphine [114]. Topical, pain-relieving naltrexone cream has
also proven successful in accelerating wound healing in in vivo studies [115]. Recently, delivery
of local anesthetics has shown success as a non-opioid pain management approach. Local
anesthetics function by blocking voltage-gated sodium channels and thus temporarily blocking
nerve conduction through nociceptive afferent nerves [116]. These therapeutics are divided into
two main groups based on their chemical structures: amides and esters. Amides are typically
safer and more widely used as they lead to less severe side effects and have low rates of patient
allergic reactions [117].
Bupivacaine, which is categorized as an amide anesthetic, is known for its slow onset
and lengthy duration of action [15]. Bupivacaine, as well as other local anesthetics, is
hydrophobic which increases both its potency and duration of action, but also increases its
toxicity and makes it difficult to deliver in sustained quantities [118]. Clinical studies have
shown that laparotomy patients treated with liposomal bupivacaine had a 30% reduction in
25

opioid use during the first 72 hours following surgery [119]. Furthermore, bupivacaine has been
shown to have both prophylactic and bactericidal effects against varying strains of
microorganisms [120]. Some studies also suggest that local anesthetics may increase blood
perfusion levels [121] and modify the inflammatory response [122], calming inflammation and
reducing edema that could lead to conversion of burn wounds to deeper layers of tissue.

Figure 4. Chemical structure of bupivacaine.

There are several formulations of creams and transdermal patches that contain local
anesthetics, with some available for over-the-counter use [123; 124]. Typical formulations of
topical creams and sprays provide rapid relief, but effects are limited in duration and require
reapplication. A number of drug delivery systems have been developed in an attempt to provide a
sustained release of local anesthetics due to the neurotoxicity and short half-lives often
associated with these molecules [125; 126]. However, few of these systems are projected to enter
clinical trials due to issues commonly associated with the use of local anesthetics such as plasma
stability, blood brain barrier permeability, and cardiotoxicity [116; 127]. One system showing
initial in vitro success loaded poly(ethylene glycol) and gelatin matrices with bupivacaine and
silver sulfadiazine to manage pain and prevent infection. Results of this study indicated that the
26

combination of therapeutics did not alter the antimicrobial effects of silver sulfadiazine, and
enhanced the release of bupivacaine [128]. Pek et al. tested poly(D,L-lactic-co-glycolic acid)
(PLGA) and poly(L-lactic acid) (PLLA) microspheres loaded with bupivacaine in vivo for
treating postoperative pain relief after knee surgery, and saw a sustained release of therapeutic
concentrations of bupivacaine for two weeks post-surgery, with no adverse side effects [129].
Bupivacaine has also been incorporated into ultra-high molecular weight polyethylene in joint
prosthetics to provide pain relief following joint replacement surgery, but this material has
limited efficacy in other applications like wound dressings [130]. Bupivacaine has also been
encapsulated into microspheres, [131; 132] polyanhydride disks, [133], and liposomes [134],
which all resulted in a significant burst release, an issue often seen with hydrophobic
therapeutics. As demonstrated by the varying results of these studies, it is clear that the selection
of the appropriate drug delivery carrier is essential to the success of bupivacaine delivery
systems.
Chitosan and electrospun chitosan membranes
Chitosan, a linear polysaccharide biopolymer, could offer a way to incorporate
biodegradable, anti-biofilm, pain management therapeutics directly into wounds (Figure 5).
Chitosan is derived from chitin, a linear polysaccharide of N-acetylglucosamine units, that is
located within the exoskeletons of crustaceans and arthropods as well as the cell walls of fungi
and yeast. This high availability means chitin and chitosan are both extremely inexpensive to
obtain [135]. Chitosan can be manufactured from chitin via partial or full deacetylation, with a
required minimum of 50% degree of deacetylation (DDA) before the polymer is considered
chitosan rather than chitin. In its final form, chitosan is comprised of randomly distributed β-(14)-2-amino-2-D-glucosamine (deacetylated) and β-(1-4)-2-acetamido-2-D-glucoseamine
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(acetylated) units, and is soluble in dilute acids [136]. Chitosan’s solubility in aqueous solutions
has led to its successful fabrication into several forms including sponges, pastes, thin films,
nanoparticles, and hydrogels. Some of the medical applications currently being investigated at
the University of Memphis include the following: chitosan sponge delivery systems [137],
magnetic chitosan nanoparticles for targeted drug delivery [138], coatings for musculoskeletal
implant fixation hardware [139], guided bone regeneration mats [140], and injectable chitosan
paste [106].
Chitosan has been shown to display antimicrobial properties against Escherichia coli, P.
aeruginosa, Staphylococcus epidermidis, and S. aureus, which may be due in part to its cationic
nature [141]. It has also been demonstrated that low-molecular-weight chitosan can penetrate
bacterial cell walls, bind with DNA, and inhibit DNA transcription and mRNA synthesis [142].
High molecular weight chitosan has been shown to bind to the negatively charged components
on the bacterial cell wall, forming an impermeable layer around the cell, changing cell
permeability and blocking transport into the bacterial cell [135]. This broad-spectrum
antimicrobial activity and low toxicity to human cells makes chitosan a promising antimicrobial
agent; however, varying results based on the molecular weight and degree of deacetylation of the
chitosan used, as well as variation based on type and age of bacteria tested, make conclusions
indefinitive [135]. Though the exact mechanism of chitosan’s antimicrobial properties is still
being researched and debated, these properties make chitosan a favorable material choice when
fabricating wound healing membranes.
Electrospinning is a membrane fabrication method that is used frequently because it
creates micro- and nano-scale fibers, which are similar to the nanoscale structures within native
tissue and thus often lead to efficient tissue regeneration and compatibility [143]. During the
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process of electrospinning, an electrical field is applied between a metallic needle and a collector
surface [144]. Due to the charge between the needle and collection surface, when a polymeric
liquid droplet is ejected from the needle, the charged fluid jet is ejected in the shape of a conical
protrusion called a Taylor cone [145]. The high surface charge allows the fluid stream to be
whipped around so that the stretched nanofiber is deposited on the collection surface with a
random pattern. The resulting fibers can differ greatly based on temperature and humidity of the
reaction site, as well as the electrical voltage, distance between the tip and collector, solution
feeding rate, and a variety of other factors [146]. Chitosan solutions can be electrospun to
produce nanofibrous membranes of varying thickness [140; 143]. These nanofibrous membranes
resemble the native fibrous structure of the extracellular matrix to support cell growth and
provide increased surface area for drug delivery.
Membranes may be modified via acylation, during which fatty acid chains are covalently
bonded to chitosan to prevent swelling and dissolution of the membrane fibers [29; 147].
Acylation forms a hydrophobic surface on the core chitosan nanofiber that minimizes adherence
of the fibers to wounded tissue, which in turn minimizes damage to fragile tissue during dressing
changes [147]. Additionally, the modification of membranes via acylation provides the potential
to retain and provide a controlled release of hydrophobic therapeutics. For instance, Murali et al.
investigated simvastatin release from electrospun chitosan membranes acylated with different
short chain fatty acids, and found each to release a sustained amount of the therapeutic for
greater than 30 days, though release amount differed by the type of short chain fatty acid
modification performed [148]. Due to previous success of modified electrospun chitosan
membranes in delivering hydrophobic therapeutics, these membranes may be applicable in
improving delivery of the hydrophobic agents C2DA and bupivacaine.
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Despite chitosan’s beneficial attributes as a wound dressing, there are also limitations to
consider when developing such applications. For example, chitosan is soluble only in diluted
organic or inorganic solvents that are below its pKa of 6.3 [149]. Furthermore, chitosan materials
vary greatly in terms of molecular weight, polydispersity index, degree of deacetylation, and
moisture content depending on the manufacturer, so products and studies involving chitosan can
be inconsistent [150]. Similarly, manufacturing conditions such as humidity and temperature can
greatly alter the final chitosan product. This final product is also often post-processed with
sterilization, thermal processing, or chemical modifications, all of which can also lead to
differing material properties [150].

Figure 5. Chemical structure of chitosan composed of β(1→4) linked units of (A) N-acetyl-Dglucosamine and (B) D-glucosamine [151].
Hexanoic acid-treated electrospun chitosan membranes (HA-ESCM) loaded with both
bupivacaine and C2DA may serve to 1) act as a barrier to microbial contamination, 2) release
local anesthetics in a controlled manner that reduce pain and modify the inflammatory response,
and 3) release the natural antimicrobial fatty acid C2DA to prevent biofilm formation. These
loaded membranes may be used as wound dressings for soft tissue wounds following medical
device implantation, musculoskeletal trauma, or burn wounds for prolonged prevention of
infection and management of pain.
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CHAPTER III
IN VITRO EVALUATION OF LOADED CHITOSAN MEMBRANES FOR PAIN
RELIEF AND INFECTION PREVENTION

ABSTRACT
Wounds resulting from surgeries, implantation of medical devices, and musculoskeletal
trauma result in pain and can also result in infection of damaged tissue. Up to 80% of these
infections are due to biofilm formation either on the surface of implanted devices or on
surrounding wounded tissue. Bacteria within a biofilm have intrinsic growth and development
characteristics that allow them to withstand up to 1000 times the minimum inhibitory
concentration of antibiotics, demonstrating the need for new therapeutics to prevent and treat
these infections. Cis-2-decenoic acid (C2DA) is known to disperse preformed biofilms and can
prevent biofilm formation entirely for some strains of bacteria. Additionally, local anesthetics
like bupivacaine have been shown to have antimicrobial effects against multiple bacterial strains.
This study sought to evaluate hexanoic acid-treated electrospun chitosan membranes (HAESCM) as wound dressings that release C2DA and bupivacaine to simultaneously prevent
infection and alleviate pain associated with musculoskeletal trauma. Release profiles of both
therapeutics were evaluated, and membranes were tested in vitro against Methicillin-resistant
Staphylococcus aureus (MRSA) to determine efficacy in preventing biofilm infection and
bacterial growth. Results indicate that membranes release both therapeutics for 72 hours, and
release profile can be tailored by loading concentration. Membranes were effective in preventing
biofilm growth but were toxic to fibroblasts when loaded with 2.5 or 5 mg of bupivacaine.
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INTRODUCTION
There is a growing demand for local delivery systems to treat and prevent infection and
alleviate pain during wound healing [116]. Biofilm infections, caused by microbial communities
adhering to the surfaces of implanted devices, surrounding tissue, and musculoskeletal wounds,
are particularly difficult to treat due to their antibiotic tolerance [32; 152]. Up to 80% of all
human infections are due to the formation of biofilm; these infections remain particularly
difficult to treat due to phenotypic changes that make bacteria within a biofilm resistant to 1000x
the typical minimum inhibitory concentration of antibiotics [8]. Once infection is present, the
removal of implanted materials and/or aggressive debridement of wounded tissue is often the
only successful strategy for treating the infection [153; 154]. Long term antibiotic use can help to
manage biofilm infections, but often fails while also increasing risk of antibiotic resistance and
toxic side effects [10]. Furthermore, overuse of aminoglycoside antibiotics can lead to
nephrotoxic and ototoxic side effects [155]. Thus, the occurrence of biofilm infections can lead
to increased hospital time and trauma for patients, as well as increased cost of care.
Bacteria within a biofilm release intrinsic signaling molecules, termed diffusible signal
factors (DSF), to trigger dispersal from the attachment surface and allow for biofilm colonization
throughout other areas of the body [11]. Previous research has shown that the DSF cis-2decenoic acid (C2DA), a short chain fatty acid, disperses mature biofilm and inhibits biofilm
formation, making this molecule a promising therapeutic to prevent wound infections [13; 156].
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Previous studies have investigated delivery of C2DA in other local delivery systems, including
chitosan/polyethylene glycol (PEG) sponges and phosphatidylcholine coatings [8; 139; 157].
However, these systems are limited due to the substantial burst release of C2DA, resulting in a
quick depletion of the therapeutic. First-order kinetic (i.e. burst) release is associated with
diffusion driven release; because phosphatidylcholine is very transient on the surface and can
form micelles to dissociate and diffuse away from the surface, C2DA diffuses with it, leading to
a substantial burst. Loading C2DA within chitosan/PEG sponges also appeared to encourage
diffusion of C2DA into surrounding media, indicating the engineering challenge of developing a
delivery system that avoids a burst release of C2DA.
In addition to infection prevention, non-opioid pain management strategies such as local
delivery of anesthetics are a top priority for wound treatment, especially as the opioid crisis
reaches epidemic proportions [14]. Studies have also confirmed that in addition to analgesic
effects, local anesthetics like bupivacaine have inherent antimicrobial effects [15]. A number of
drug delivery systems have been developed in an attempt to provide a sustained release of local
anesthetics to combat the neurotoxicity and short half-lives often associated with these molecules
when delivered systemically [117; 125; 127]. However, few of these systems are projected to
enter clinical trials due to issues commonly associated with the use of local anesthetics such as
plasma stability, blood brain barrier permeability, and cardiotoxicity [116; 127]. For instance,
Pek et al. tested poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(L-lactic acid) (PLLA)
microspheres loaded with bupivacaine in vivo for treating postoperative pain relief after knee
surgery, and saw a sustained release of therapeutic concentrations of bupivacaine for two weeks
post-surgery, with no adverse side effects [129]. Bupivacaine has been incorporated into ultrahigh molecular weight polyethylene in joint prosthetics to provide pain relief following joint
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replacement surgery, but this material has limited efficacy in other applications like wound
dressings [130]. There are several formulations of creams and transdermal patches that contain
local anesthetics, with some available for over-the-counter use [123; 124]. Though formulations
of topical creams and sprays provide rapid relief, effects are limited in duration and require
reapplication.
Because of the limited therapeutic release duration provided by previous systems, a
delivery system is needed to reduce the initial burst release and provide a sustained release of
these infection and pain preventing molecules. Chitosan is a biocompatible polymer that has
been investigated in several applications, including wound and bone healing [135]. Electrospun
chitosan membranes can provide a template for healing tissue, coverage of wounds, and drug
delivery following injury. These nanofibrous membranes resemble the native fibrous structure of
the extracellular matrix to support cell growth and provide increased surface area for drug
delivery. Membranes are modified via acylation, during which fatty acid chains are covalently
bonded to chitosan to prevent swelling and dissolution of the membrane fibers [29]. Acylation
forms a hydrophobic surface on the core chitosan nanofiber that minimizes adherence of the
fibers to wounded tissue, which in turn minimizes damage to fragile tissue during dressing
changes. Additionally, the modification of membranes via acylation provides the potential to
retain and provide controlled release of hydrophobic therapeutics. Due to previous success of
modified electrospun chitosan membranes in delivering hydrophobic therapeutics [148], these
membranes may be applicable in delivering the hydrophobic compounds (or agents) C2DA and
bupivacaine.
Chitosan membranes loaded with both bupivacaine and C2DA may serve to 1) act as a
barrier to microbial contamination, 2) release local anesthetics in a controlled manner that reduce
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pain and modify the inflammatory response, and 3) release the antimicrobial fatty acid C2DA to
prevent biofilm formation. These loaded membranes may be used as wound dressings for soft
tissue wounds following medical device implantation, musculoskeletal trauma, or burn wounds
for prolonged prevention of infection and management of pain. In this study we sought to
determine release profiles of therapeutics from chitosan membranes, their ability to prevent
Methicillin-resistant Staphylococcus aureus (MRSA) growth and biofilm formation, and their
compatibility with fibroblast cells.

RESULTS
Elution
Bupivacaine elution
When bupivacaine was loaded into HA-ESCM without C2DA, it eluted with an initial
burst release for the highest concentration, but a reduced burst for lower concentrations (Figure
4). This was followed by a sustained release for the 10 mg and 5 mg loading groups at levels
averaging approximately 0.5 mg per day per membrane disc (Figure 6). Percentage of total
bupivacaine released was markedly lower for the 1.25 mg loaded group compared to the three
higher concentrations (Table 1). Following results of this elution study, 5 mg and 2.5 mg
bupivacaine loading concentrations were selected for dual-loaded membranes as these produced
a sustained release with a lower burst than the 10 mg loading concentration, and a higher
percentage release than the 1.25 mg loading group.
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A

B

Figure 6. Graphs detailing (A) bupivacaine release and (B) cumulative bupivacaine release by
HA-ESCM loaded with 10, 5, 2.5 or 1.25 mg of bupivacaine throughout 72-hour elution study.
Release was determined by high performance liquid chromatography (HPLC). Data is
represented as mean ± standard deviation (n=5). Lines connecting points are intended to guide
the eye.
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Table 1. Percentage of total bupivacaine released for each loading concentration throughout 72hour elution study.
Loading amount

Percent released

10 mg

90.14%

5 mg

~100%

2.5 mg

75.36%

1.25 mg

7.47%

C2DA elution
C2DA eluted from membranes with no significant burst, showing a sustained release throughout
the course of three days, differing by loading concentration (Figure 7). Percentage of total
therapeutic released was determined for each group following 72-hour elution (Table 2).
Following results of this elution study, 25 μg and 12.5 μg loading concentrations were selected
for future tests as these produced the highest cumulative release of C2DA.

A
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B

Figure 7. Graphs detailing (A) C2DA release and (B) cumulative C2DA release by HA-ESCM
loaded with 25, 12.5, 6.25, or 3.125 μg of C2DA throughout 72-hour elution study. Release was
determined by high performance liquid chromatography (HPLC). Data is represented as mean ±
standard deviation (n=5). Lines connecting points are intended to guide the eye.

Table 2. Percentage of total C2DA released for each loading concentration throughout 72-hour
elution study.
Loading amount

Percent released

25 μg

46.25%

12.5 μg

70.08%

6.25 μg

~100%

3.125 μg

22.09%

Bupivacaine/C2DA combination elution
When bupivacaine and C2DA were dually loaded into membranes, bupivacaine released
with an initial burst of about 1.6 mg for the 5 mg loading concentration and 1 mg for the 2.5 mg
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loading concentration, followed by a much lower sustained release. Though there were slight
differences of bupivacaine release depending on C2DA concentration, the amount of C2DA
loaded did not significantly alter the total amount of bupivacaine released (p>0.05, determined
by ANOVA with Holm-Šídák post-hoc tests) (Figure 8). Percentage of total therapeutic released
was determined for each group following 72-hour elution (Table 3). For groups loaded with 5
mg of bupivacaine, release was significantly higher for single-loaded membranes starting at the
24-hour timepoint. However, the opposite was true for membranes loaded with 2.5 mg
bupivacaine.

A
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B

Figure 8. Graphs of (A) bupivacaine release and (B) cumulative bupivacaine release from dualloaded HA-ESCM. Data is represented as mean ± standard deviation (n=5). Lines connecting
points are intended to guide the eye.

Table 3. Percentage of total bupivacaine released for each dual-loaded concentration
throughout 72-hour elution study.
Loading amount

Percent released

5 mg B/25 μg C

72.22%

5 mg B/12.5 μg C

66.68%

2.5 mg B/25 μg C

93.56%

2.5 mg B/12.5 μg C

75.29%

C2DA released from dual loaded membranes with a slight burst during the first 12 hours,
followed by a lower sustained release for the last 60 hours. As seen with bupivacaine release
from dual loaded membranes, there were slight differences of C2DA release depending on
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bupivacaine loading concentration, but the amount of bupivacaine loaded did not significantly
alter the total amount of C2DA released. Further, there was no significant difference between
C2DA release from single or dual-loaded membranes (p>0.05, determined by ANOVA with
Holm-Šídák post-hoc tests) (Figure 9). Percentage of total therapeutic released was determined
for each group following 72-hour elution (Table 4).

A

B
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Figure 9. C2DA release from dual-loaded membranes. Graphs of (A) C2DA release and (B)
cumulative C2DA release from dual loaded membranes modified by hexanoyl acylation. Data is
represented as mean ± standard deviation (n=5). Lines connecting points are intended to guide
the eye. Significance was determined by ANOVA with Holm-Šídák post-hoc tests.

Table 4. Percentage of total C2DA released for each dual-loaded concentration throughout 72hour elution study.
Loading amount

Percent released

5 mg B/25 μg C

~100%

5 mg B/12.5 μg C

~100%

2.5 mg B/25 μg C

~100%

2.5 mg B/12.5 μg C

~100%

Zone of inhibition
Results of Kirby-Bauer Zone of Inhibition studies (Table 5) show highest therapeutic
release by groups containing 25 μg of C2DA, while unloaded membranes, membranes loaded
with just bupivacaine, and membranes loaded with the lower C2DA concentration did not
produce significant zones. Representative images are included to demonstrate zones produced by
different membranes groups (Figure 5).
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Table 5. Table indicating 24-hour Zone of Inhibition (mm) against Methicillin-resistant S.
aureus, measured using ImageJ software (NIH), for each membrane type (n=4). ± represents
standard deviation. * indicates significantly higher zone than paper disk control, as determined
by one-way ANOVA with Holm-Šídák post-hoc tests (p<0.05).

Loading concentration

Zone of inhibition (mm)

5 mg BUP

0.84± 0.48

2.5 mg BUP

0.62 ± 0.42

25 μg C2DA

3.09 ± 0.29*

12.5 μg C2DA

1.23 ± 0.25*

5 mg BUP + 25 μg C2DA

3.48 ± 0.98*

5 mg BUP + 12.5 μg C2DA

0.16 ± 0.07

2.5 mg BUP + 25 μg C2DA

2.99 ± 0.09*

2.5 mg BUP + 12.5 μg C2DA

0.16 ± 0.03

Unloaded membrane

0.15 ± 0.01

Paper disk control

0.00 ± 0.00

Vancomycin control*

4.19 ± 0.49
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Controls

Negative (blank)
Bup 0

Positive (vancomycin)
Bup 2.5

Bup 5

C2DA 0

C2DA 12.5

C2DA 25

Figure 10. Representative images of ZOI for each membrane group and control groups.
Biofilm growth assays
For the first study measuring viability of planktonic S. aureus, all membranes freshly
loaded with therapeutics resulted in significantly less viable bacteria (p<0.05) compared to both
gauze and chitosan sponge controls. Unloaded membranes prior to 72-hour elution, as well as
membranes with 25 μg of C2DA after 72-hour elution, resulted in less viable planktonic bacteria
growth than was seen in the gauze controls (Figure 11).
The following study quantified biofilm growth on membranes after 24-hour incubation
with S. aureus. Almost all membrane groups allowed significantly less biofilm growth (p<0.05)
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compared to gauze and chitosan sponge controls. The only exception was the unloaded
membranes after 72-hour elution, which was only significantly lower than the gauze controls
(Figure 12).
The final biofilm study quantified growth of biofilm in wells beneath membranes. Most
membrane groups allowed for significantly less biofilm growth (p<0.05) in wells compared to
both chitosan sponge and gauze controls, with the exception of the post-elution unloaded group
and the post-elution group loaded with 2.5 mg of bupivacaine (Figure 13).

Figure 11. Planktonic bacteria growth. Graphical representation of planktonic S. aureus
growth in direct contact with membranes or controls (n=4). Amount of viable bacteria was
quantified based on metabolic activity by measuring ATP production. Results were then
normalized as a percentage compared to untreated control wells. ** indicates significant
difference (p<0.05) between groups and both gauze and chitosan sponge controls. * indicates
significant difference (p<0.05) between groups and gauze controls. Significance was determined
by ANOVA with Holm-Šídák post-hoc tests.
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Figure 12. Biofilm growth on membranes. Graphical representation of S. aureus biofilm
growth on membranes or controls (n=4). Amount of viable bacteria was quantified based on
metabolic activity by measuring ATP production. Results were then normalized as a percentage
compared to untreated control wells. ** indicates significant difference (p<0.05) between groups
and both gauze and chitosan sponge controls. * indicates significant difference (p<0.05) between
groups and gauze controls. Significance was determined by ANOVA with Holm-Šídák post-hoc
tests.
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Figure 13. Biofilm growth in wells. Graphical representation of S. aureus biofilm growth in
wells beneath membranes or controls (n=4). Amount of viable bacteria was quantified based on
metabolic activity by measuring ATP production. Results were then normalized as a percentage
compared to untreated control wells. a indicates groups that have significantly less biofilm
growth (p<0.05) than both b and c groups. b indicates groups that have significantly less biofilm
growth (p<0.05) than c groups. Significance was determined by ANOVA with Holm-Šídák posthoc tests.

Cytocompatibility
All membrane types except those loaded with only C2DA were below the accepted 70% viability
value when normalized to the blank standard, in accordance with the ISO 109935 Biological
Evaluations of Medical Devices standard when evaluating biomaterials against fibroblasts; the
C2DA loaded membranes and the chitosan sponge control all had significantly higher viability
than any groups containing bupivacaine (Figure 14).
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Figure 14. HA-ESCM cytocompatibility with fibroblasts. Graphical representation of
cytocompatibility results for each membrane type when evaluated with L929 fibroblasts cells
(n=5). Amount of viable fibroblasts was quantified based on metabolic activity by measuring
ATP production. Results were then normalized as a percentage compared to untreated control
wells. Error bars indicate standard deviation and the red bar line represents the accepted value of
70% according to ISO 10993-5.

DISCUSSION
HA-ESCM were capable of being loaded with C2DA and bupivacaine, individually or in
combination, to prevent biofilm formation. This material shows prospective use as a wound
dressing following surgery, implantation of a medical device, or musculoskeletal trauma.
Loading therapeutics via ethanol evaporation allows HA-ESCM to be usable almost
immediately, indicating their potential for patient-specific loading at time of care. Local
anesthetic-loaded wound dressings may alleviate the need for patients to manage pain with
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systemic opioids, which often leads to unwanted consequences like opioid misuse, dependence,
and consequential addiction [158]. In addition to providing physical coverage from bacterial
contamination, the use of the antimicrobial biopolymer chitosan as wound dressing material
provides intrinsic infection resistance. This resistance only increases with the addition of
bupivacaine, which kills bacteria at higher concentrations, as well as C2DA, which disperses
bacteria to prevent biofilm formation [120]. Together, these three antimicrobial components
function to prevent pain and infection associated with wounds, which in turn may decrease the
need for revision surgeries or tissue debridement required after development of complex biofilm
infections.
The slight burst seen during the first 6 hours of membranes loaded with bupivacaine only
may indicate that bupivacaine is being loaded in excess of the amount soluble within the acyl
layer of chitosan membranes. This may imply that rather than loading within spaces between
acylated fibers, the excess bupivacaine could dry on top of membranes and thus release instantly
from the surface. Median values of 5 mg and 2.5 mg of bupivacaine were chosen because the 10
mg loading concentration saw the highest proportional burst release of 5 mg, which based on
other studies was likely a toxic amount [159]. When combining bupivacaine with C2DA, release
followed a similar pattern, with a slight burst during the first timepoint followed by a sustained
average release of about 0.25 mg per time point, which is below previously reported toxic levels
of 0.6 mg/ml [160]. C2DA release from membranes loaded with only C2DA followed a zeroorder release profile, contrasting with previous attempts to deliver C2DA. For instance, C2DA
release from chitosan sponges was sustained throughout 5 days, but also saw a burst release
during the first day [156], and phosphatidylcholine coatings loaded with C2DA saw a similar
variable release profile, with the majority of C2DA releasing as a burst during the first 24 hours
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[139]. Furthermore, combining both therapeutics may cause interactions that alter release
profiles, as demonstrated by the slightly lower bupivacaine release when dually loaded with
C2DA. When C2DA was loaded with bupivacaine, release followed a first-order release pattern,
differing from the zero-order release seen when C2DA was loaded alone. High variability in
C2DA elution may be decreased by modifying HPLC protocols to improve detection of C2DA at
low quantities. Furthermore, extraction can be used to resuspend C2DA in more accurate,
detectable concentrations. Similar studies have shown that hexanoic anhydride-treated
membranes retain more therapeutics compared to membranes treated with other short chain fatty
acids such as acetic anhydride and butyric anhydride; thus, modifying with another fatty acid
may allow for higher cumulative release of hydrophobic therapeutics [148].Future studies will
include repeated tests with other concentrations of each therapeutic to better elucidate release
mechanisms, which in turn may explain inconsistencies. Tests will also be repeated using other
elution media, including fetal bovine serum (FBS)-containing media, since the presence of
protein is known to affect the release of hydrophobic substances [161].
The minimal zones (< 1 mm) around bupivacaine-loaded membranes suggest that
bupivacaine does not diffuse from membranes to the same extent as C2DA, though small zones
may indicate potential effectiveness in preventing bacterial attachment. While this test is useful
in recognizing initial interactions between materials and bacteria, zones are highly dependent on
diffusion so results may not give the full scope of antimicrobial characteristics. For further
confirmation of initial antimicrobial results, three separate but related biofilm assays were
conducted. First, there was significantly more viable planktonic bacteria for all groups after
elution compared to the freshly loaded membranes, which may be due in part to the slight initial
burst release of therapeutics seen by all groups; higher concentrations released during the first 24
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hours may be sufficient in killing bacteria that contacts the membranes, rather than just
preventing growth on the membranes. Biofilm assays determining biofilm growth on the
membranes demonstrated that the membrane materials and therapeutics were all capable of
inhibiting biofilm growth to a significant extent. Inhibition after the full course of elution for
loaded membranes suggests that membranes are still retaining a small but active amount of these
antimicrobials. Viability quantification of biofilm growth on wells beneath membranes showed
that growth was minimal for all membrane groups compared to gauze and control chitosan
sponge, suggesting that biofilm inhibitors are released from membranes at amounts that would
keep biofilm from forming on sites distant to the material, which is beneficial in wound healing.
Other studies have strongly suggested that electrospun chitosan nanofibers can interact with
bacterial cell walls to rupture and cause leakage of intracellular components, which may explain
why even unloaded chitosan membrane groups were successful in preventing biofilm growth
[162]. It is also worth noting that the total amount of C2DA loaded within membranes is lower
than that loaded into previous delivery systems [139; 156; 157], but antimicrobial activity is
maintained. These results are consistent with previous studies that found nanomolar amounts of
C2DA to be active against bacteria [13; 52; 163]. Future studies can expand on these to evaluate
different types of strains of pathogenic microorganisms and image biofilm formed on materials
using SEM or fluorescence assays.
Results of cytocompatibility studies showed that the concentrations of C2DA were
compatible with fibroblasts, whereas both concentrations of bupivacaine were toxic to
fibroblasts. While unfavorable, the results demonstrating bupivacaine’s toxicity to fibroblasts
were consistent with other studies. At concentrations of 0.3 mg/ml, bupivacaine is compatible
with fibroblasts but reduces cell viability below 25% at a 0.6 mg/ml concentration [160]. Due to
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the higher burst release seen during the first 6 hours of elution, it is feasible that bupivacaine
loading may affect fibroblast growth during the first few hours. However, other dermal cell types
such as keratinocytes may be more tolerant to higher concentrations of bupivacaine [164]. The
toxic effect of bupivacaine could be addressed by either determining a lower functional loading
concentration, or trying other local anesthetics with less toxic effects on fibroblasts, such as
lidocaine or ropivacaine [160; 164]. High serum concentrations of all local anesthetics can cause
mitochondrial dysfunction and disturbed oxidative phosphorylation, both of which can lead to
seizures, cardiac arrythmias, and hypotension [117]. Bupivacaine specifically is known to be
more toxic, especially in tissues with high aerobic demand and low tolerance for hypoxia [165].
This pilot study investigating loaded HA-ESCM for pain relief and infection prevention
suggests that membrane materials and loaded membranes are capable of preventing MRSA
growth on their surface. Loaded HA-ESCM were also sufficient in releasing active amounts to
inhibit biofilm on surfaces beneath membranes, indicating their potential use as dressings to
prevent biofilm colonization of open tissue. Despite the initial signs of success of this delivery
system, some limitations remain, including generalization of results in vitro to in vivo effects,
assessment of just one bacterial strain, and evaluation of a limited number of loading scenarios.
Future studies will determine loading capacity and loading efficiency for both to design loading
for a sustained release profile and minimal cytotoxicity. Lower concentrations of bupivacaine
will be tested with human fibroblasts and keratinocytes as well as immune cells to ensure this
system’s cytocompatibility. Bacterial studies will be repeated with S. aureus validate results, in
addition to new assays with other bacterial strains such as Pseudomonas aeruginosa and
Acinetobacter baumannii. Overall, this in vitro study indicates the potential success of loaded
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HA-ESCM in releasing therapeutics and preventing microbial growth, making it a promising
wound dressing material to provide pain relief and infection prevention.

MATERIALS AND METHODS
Fabrication
Membranes were electrospun using a 71% degree of deacetylation, 311.5 kDa chitosan
(Primex) at 5.5 (w/v) % in 70% (v/v) trifluoroacetic acid - 30% (v/v) dichloromethane solution at
26kV as previously described [140; 147]. Membranes were spun to 15 cm diameters and ~ 0.7
mm (30 ml spinning solution) thickness and treated using a 50-50 solution of pyridine and
hexanoic anhydride [147]. Membranes were punched into 1 cm diameter discs and UV sterilized
prior to contact with fibroblasts or bacterial cells. Ethanol (200 proof) was used for loading
therapeutics [148]. Membranes were loaded with either C2DA (3.125, 6.25, 12.5, or 25 μg),
bupivacaine (1.25, 2.5, 5, or 10 mg), or a combination of both treatments, then dried aseptically
in a laminar flow hood.
Elution
Elution studies were conducted on HA-ESCM loaded with varying concentrations of
C2DA, bupivacaine, or combinations of both therapeutics. Loaded HA-ESCM (n=5 per
group) were placed in sterile phosphate buffered saline (PBS) and eluates were collected by
complete solution change at time points of 3, 6, 9, 12, 24, 36, 48, 60, and 72 h. The concentration
of C2DA and bupivacaine in the eluates was measured with high performance liquid
chromatography (HPLC) using a ThermoScientific Dionex Ultimate 3000 Series HPLC system
(Table 6). All eluate concentrations were normalized to standard curves with known
concentrations of C2DA and bupivacaine.

53

Table 6. HPLC settings used for detection of bupivacaine and C2DA.
Bupivacaine

C2DA

Column

C18 100x2.1mm

C18 100x2.1mm

Mobile phase

Buffer : Acetonitrile

Buffer : Acetonitrile : 10%

(50 : 50)

Methanol (5 : 75 : 20)

Buffer

KH2PO4 + N(CH₂CH₃)₃ MeOH+ H2O + H3PO4
+ H2O + H3PO4

Wavelength

220 nm

210 nm

Flow rate

1 mL/min

0.3 mL/min

Column oven

45° C

45° C

temperature

Zone of inhibition (ZOI) studies
To determine the baseline antimicrobial characteristics of the HA-ESCM, membrane
groups were evaluated in modified Kirby-Bauer zone of inhibition assays: freshly loaded
membranes, blank paper disc controls, and vancomycin-loaded paper disk controls. Overnight
growths of bacteria (Methicillin-resistant S. aureus (MRSA) (ATCC 33591)) at concentrations of
105 colony forming units (CFU) were combined in trypticase soy broth (TSB) and added to
tryptic soy agar plates to form bacterial lawns. HA-ESCM loaded with bupivacaine, C2DA, or a
combination of both were placed on bacterial lawns and incubated at 37° C for 24 hours.
Resulting zones were measured using ImageJ software and compared to vancomycin controls as
well as paper disk controls.
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Biofilm assays
Biofilm inhibitory properties were tested by direct inoculation of freshly loaded HAESCM and membranes after elution in PBS for 72 hours. Membranes were placed in 48 well
plates and inoculated with 0.5 mL tryptic soy broth (TSB) containing 106 colony forming units
(CFU) of S. aureus. After incubating at 37° C for 24 hours, membranes were removed from
wells, rinsed twice with sterile PBS, and sonicated for 5 minutes at 40 kHz (Fisher Scientific
Ultrasonic Bath, 9.5 L) to remove biofilm-associated bacteria. Quantification of biofilm was
determined using BacTiter-Glo® Microbial Cell Viability Assay (Promega).
The presence of viable planktonic bacteria was determined for wells with membranes.
Supernatant from wells containing membranes and bacteria was removed and added to a new 96
well plate, then combined with BacTiter-Glo® to quantify the amount of planktonic bacterial
growth after 24 hours exposure to membranes.
Biofilm growth on tissue culture plastic for wells containing membranes was further
analyzed to further determine effects on biofilm formation at sites off of the membrane itself.
After membranes and supernatant were removed, wells were rinsed with PBS and attached
biofilm was quantified using BacTiter-Glo®. Results were normalized as a percent viability
versus bacterial cells grown in untreated wells and also compared to a control group of chitosan
sponges and gauze.
Cytocompatibility
An adaptation of ISO 10993-5 (“Biological evaluation of medical devices — Part 5:
Tests for in vitro cytotoxicity”) was used to evaluate membrane cytocompatibility with
fibroblasts. HA-ESCM were evaluated alone, as well as loaded with bupivacaine, C2DA, or
combinations of both. Fibroblasts (L929, Lonza) were seeded at 1 x 104 cells/ cm2 in 12-well
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plates and grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine
serum and 100 µg/mL of Normocin antibiotic/antimitotic solution for 24 hours at 37 °C and 5%
CO2. After overnight incubation, membranes were placed within the upper chamber of
transwells. After 24 hours, wells were imaged microscopically, and cell viability was quantified
using the CellTiter-Glo® viability assay (Promega). Results were normalized as a percent
viability versus cells grown on blank tissue culture plastic and also compared to a control group
of chitosan sponges.
Statistical analysis
Statistical analysis was performed using SigmaPlot and GraphPad Prism 7.2 software
(GraphPad Software Incorporation, La Jolla, CA, USA). Data was assessed first by performing
Shapiro-Wilk normality test, followed by Brown-Forsythe equal variance test. If both passed,
data was further analyzed with a one-way analysis of variance (ANOVA) followed by HolmSidak’s post-hoc analysis to detect significant between experimental groups (α = 0.05). If
normality and equal variance were not passed, data was analyzed using Kruskal-Wallis ANOVA
on ranks, followed by Tukey post-hoc test.
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CHAPTER IV
DISCUSSION
Hexanoyl-acylated electrospun chitosan membranes were capable of being loaded with
C2DA and bupivacaine, individually or in combination, to prevent biofilm formation. This
material shows prospective use as a wound dressing following surgery, implantation of a medical
device, or musculoskeletal trauma. Loading therapeutics via ethanol evaporation allows
membranes to be usable almost immediately, indicating their potential for patient-specific
loading at time of care. Local anesthetic-loaded wound dressings may alleviate the need for
patients to manage pain with systemic opioids, which often leads to unwanted consequences like
opioid misuse, dependence, and consequential addiction [158]. In addition to providing physical
coverage from bacterial contamination, the use of the antimicrobial biopolymer chitosan as
wound dressing material provides intrinsic infection resistance. This resistance only increases
with the addition of bupivacaine, which kills bacteria at higher concentrations, as well as C2DA,
which disperses bacteria to prevent biofilm formation [120]. Together, these three antimicrobial
components function to prevent pain and infection associated with wounds, which in turn may
decrease the need for revision surgeries or tissue debridement required after development of
complex biofilm infections.
Prior to this study, preliminary results showed that HA-ESCM are capable of being
loaded with and subsequently releasing maximal concentrations of both C2DA and bupivacaine
(Appendix 1). The slight burst seen during the first 6 hours of membranes loaded with
bupivacaine only may indicate that bupivacaine is being loaded in excess of the amount soluble
within the acyl layer of chitosan membranes. Median values of 5 mg and 2.5 mg of bupivacaine
were chosen because the 10 mg loading concentration saw the highest proportional burst release
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of 5 mg, which based on other studies was likely a toxic amount [159]. When combining
bupivacaine with C2DA, release followed a similar pattern, with a slight burst during the first
timepoint followed by a sustained average release of about 0.25 mg per time point, which is
below previously reported toxic levels of 0.6 mg/ml [160]. C2DA release from membranes
loaded with only C2DA followed a zero- order release profile, contrasting with previous attempts
to deliver C2DA. For instance, C2DA release from chitosan sponges was sustained throughout 5
days, but also saw a burst release during the first day [156], and phosphatidylcholine coatings
loaded with C2DA saw a similar variable release profile, with the majority of C2DA releasing as
a burst during the first 24 hours [139]. Furthermore, combining both therapeutics may cause
interactions that alter release profiles, as demonstrated by the slightly lower bupivacaine release
when dually loaded with C2DA. When C2DA was loaded with bupivacaine, release followed a
first-order release pattern, differing from the zero-order release when C2DA was loaded alone.
Similar studies have shown that hexanoic anhydride-treated membranes retain more therapeutics
compared to membranes treated with other short chain fatty acids such as acetic anhydride and
butyric anhydride; thus, modifying with another fatty acid may allow for higher cumulative
release of hydrophobics [148]. Future studies will include repeated tests with other
concentrations of each therapeutic to better elucidate release mechanisms, which in turn may
explain inconsistencies. Tests will also be repeated using other elution media, including fetal
bovine serum (FBS)-containing media, since the presence of protein is known to affect the
release of hydrophobic substances [161].
The minimal zones around bupivacaine-loaded membranes suggest that bupivacaine does
not diffuse from membranes to the same extent as C2DA, though they appear effective in
preventing bacterial attachment. While this test is useful in recognizing initial interactions
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between materials and bacteria, zones are highly dependent on diffusion so results may not give
the full scope of antimicrobial characteristics. For further confirmation of initial antimicrobial
results, three separate but related biofilm assays were conducted. Preliminary studies indicated
the success of these membranes in preventing P. aeruginosa biofilm formation and suggested
that bupivacaine and C2DA may have a synergistic relationship in preventing microbial growth
(Appendix 2-3). After adapting these early studies for S. aureus, there was significantly more
viable planktonic bacteria for all groups after elution compared to the freshly loaded membranes,
which may be due in part to the slight initial burst release of therapeutics seen by all groups;
higher concentrations released during the first 24 hours may be sufficient in killing bacteria that
contacts the membranes, rather than just preventing growth on the membranes. Biofilm assays
determining biofilm growth on the membranes demonstrated that the membrane materials and
therapeutics were all capable of inhibiting biofilm growth to a significant extent. Inhibition after
the full course of elution for loaded membranes suggests that membranes are still retaining a
small but active amount of these antimicrobials. Viability quantification of biofilm growth on
wells beneath membranes showed that growth was minimal for all membrane groups compared
to gauze and control chitosan sponge, suggesting that biofilm inhibitors are released from
membranes at amounts that would keep biofilm from forming on sites distant to the material,
which is beneficial in wound healing. Other studies have strongly suggested that electrospun
chitosan nanofibers can interact with bacterial cell walls to rupture and cause leakage of
intracellular components, which may explain why even unloaded chitosan membrane groups
were successful in preventing biofilm growth [162]. It is also worth noting that the total amount
of C2DA loaded within membranes is lower than that loaded into previous delivery systems
[139; 156; 157], but antimicrobial activity is maintained. These results are consistent with
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previous studies that found nanomolar amounts of C2DA to be active against bacteria [13; 52;
163]. Future studies can expand on these to evaluate different types of strains of pathogenic
microorganisms and image biofilm formed on materials using SEM or fluorescence assays.
Results of cytocompatibility studies showed that the concentrations of C2DA were
compatible with fibroblasts, whereas both concentrations of bupivacaine were toxic to
fibroblasts. While unfavorable, the results demonstrating bupivacaine’s toxicity to fibroblasts
were consistent with other studies. At concentrations of 0.3 mg/ml, bupivacaine is compatible
with fibroblasts but reduces cell viability below 25% at a 0.6 mg/ml concentration [160]. Due to
the higher burst release seen during the first 6 hours of elution, it is feasible that bupivacaine
loading may affect fibroblast growth during the first few hours. However, other dermal cell types
such as keratinocytes may be more tolerant to higher concentrations of bupivacaine [164]. The
toxic effect of bupivacaine could be addressed by either determining a lower functional loading
concentration, or trying other local anesthetics with less toxic effects on fibroblasts, such as
lidocaine or ropivacaine [160; 164]. High serum concentrations of all local anesthetics can cause
mitochondrial dysfunction and disturbed oxidative phosphorylation, both of which can lead to
seizures, cardiac arrythmias, and hypotension [117]. Bupivacaine specifically is known to be
more toxic, especially in tissues with high aerobic demand and low tolerance for hypoxia [165].
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CHAPTER V
CONCLUSIONS
This pilot study investigating loaded chitosan membranes for pain relief and infection
prevention suggests that membrane materials and loaded membranes are capable of preventing
MRSA growth on their surface. These membranes were also sufficient in releasing active
amounts to inhibit biofilm on surfaces beneath membranes, indicating their potential use as
dressings to prevent biofilm colonization of open tissue. Despite the initial signs of success of
this delivery system, some limitations remain, including generalization of results in vitro to in
vivo effects, assessment of just one bacterial strain, and evaluation of a limited number of
loading scenarios. Future studies will determine loading capacity and loading efficiency for both
to design loading for a sustained release profile and minimal cytotoxicity. Lower concentrations
of bupivacaine will be tested with human fibroblasts and keratinocytes as well as immune cells
to ensure this system’s cytocompatibility. Bacterial studies will be repeated with S. aureus
validate results, in addition to new assays with other bacterial strains such as Pseudomonas
aeruginosa and Acinetobacter baumannii. Overall, this in vitro study indicates the success of
loaded chitosan membranes in releasing therapeutics and preventing microbial growth, making it
a promising wound dressing material to provide pain relief and infection prevention.
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CHAPTER VI
FUTURE WORK
There are numerous studies planned to continue the evaluation of electrospun chitosan
membranes and related anti-biofilm systems. As previously mentioned, elution studies and
biofilm assays will be performed using other therapeutic concentrations as well as other bacterial
strains. Cytocompatibility studies will be repeated using human dermal fibroblasts and
keratinocytes. Additionally, effects of membranes, bupivacaine, and C2DA on immune cells will
be explored through assays to measure effects on the polarization of human macrophages toward
inflammatory phenotype (M1) or anti-inflammatory, pro-healing phenotype (M2) to determine
whether membranes promote healing and/or direct inflammatory responses that might lead to
burn wound conversion. For in vivo characterization of this delivery system as a wound dressing,
a comb scald wound model will be performed and compared to commercially available wound
care materials. The scald wounds will be inoculated with bacteria to determine the antimicrobial
characteristics of loaded membranes as well as their functionality in healing burn wounds. In
collaboration with the University of Memphis Chemistry department, other synthetics analogs of
C2DA have been developed, so future studies may include incorporation of these analogs into
chitosan membranes and evaluation of their potential to prevent and eradicate biofilm more
effectively than C2DA. Finally, other methods of attachment of fatty acids and membranes will
be investigated, such as direct acylation of C2DA or analogs to membrane or click chemistry
reactions to directly attach the reactive azide group of chitosan with the reactive alkyne tail
groups of synthetic DSF analogs.
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APPENDIX A
Initial Release Profile of Bupivacaine from Membranes
Rationale and Methods
Prior to investigations into release profiles of different bupivacaine and C2DA
concentrations from membranes, preliminary data was required to determine whether either
would release at all, and if so to what extent. While it is ideal for therapeutic concentrations of
bupivacaine to release daily to ensure pain relief, bupivacaine is known to have a series of
unwanted side effects including neurotoxicity and cardiotoxicity, so it is essential to ensure daily
and cumulative release fall below toxic ranges. The loading amount for bupivacaine was chosen
to be 20 mg, scaled down from the maximum clinical dose used in spinal anesthesia and thus
larger than would be necessary for wound care, but would provide a preliminary indication of the
maximum possible release from membranes. The maximum non-toxic C2DA concentration has
been reported to as 500 μg/mL, so this concentration was selected for initial loading. Elution
studies were conducted on membranes loaded with either 20 mg bupivacaine or 500 μg of
C2DA. Loaded membranes (n=5 per group) were placed in sterile phosphate buffered saline
(PBS) and eluates were collected by complete solution change at time points of 3, 6, 9, 12, 24,
36, 48, 60, and 72 h. The concentration of C2DA and bupivacaine in the eluates was measured
with high performance liquid chromatography (HPLC) using a ThermoScientific Dionex
Ultimate 3000 Series HPLC system (Table 6). All eluate concentrations were normalized to
standard curves with known concentrations of C2DA and bupivacaine. Percent release was
calculated to determine how much of both therapeutics was being retained by membranes.
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Results
Bupivacaine eluted from membranes with an initial burst release followed by a sustained release,
indicating that the local anesthetic will continue to release from the membrane for at least three
days (Figure 15). C2DA eluted from membranes somewhat similarly to bupivacaine, with an
initial burst during the first 12 hours followed by a gradual decrease in release throughout the
course of three days (Figure 16).

6

Bupivacaine (mg)

5
4
3
2
1
0
0

10

20

30

40

50

60

70

80

A

Bupivacaine (mg)

Hour
16
14
12
10
8
6
4
2
0
0

10

20

30

40

Hour

50

60

70

80

B

Figure 15. Graphs of elution of (A) hourly bupivacaine release and (B) cumulative bupivacaine
released by membranes loaded with 20 mg bupivacaine and modified by hexanoyl acylation.
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Figure 16. Graphs of elution of (A) hourly C2DA release and (B) cumulative C2DA released by
membranes loaded with 500 μg C2DA and modified by hexanoyl acylation.

Conclusions
C2DA and bupivacaine both eluted from membranes over the course of 72 hours using
initial maximum loading concentrations of each. These results indicate the success of this system
in releasing hydrophobic therapeutics, though high variability in C2DA release at most time
point indicates the need for repeated tests to confirm accuracy of results. For future studies,
lower concentrations of each therapeutic will be utilized and assessed.
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APPENDIX B
Synergy between Bupivacaine and C2DA analog
Rationale & Methods
When delivering combinations of multiple therapeutics together, it is first helpful to
determine whether their relationship is additive, synergistic, or antagonistic. Knowledge of
potential synergy invites the possibility of trying different and possible lower loading
concentrations of each. Prior to loading both therapeutics into membranes, synergy between
bupivacaine and a diffusible signal factor analog of C2DA (2-heptylcyclopropane-1-carboxylic
acid) was investigated against P. aeruginosa. In this study, bupivacaine was added to wells in a
series of concentrations and used either alone or in combination of 250 μg of the C2DA analog
(n=4 per group) (Table 7). Wells were inoculated with 105 colony forming units from an
overnight growth of P. aeruginosa (ATCC strain 27317) combined in trypticase soy broth
(TSB). Turbidity readings were performed using a Biotek Synergy™ H1 microplate reader, with
increased turbidity readings indicating a higher number of viable cells. Percent viability was
determined using positive (TSB alone) and negative (ethanol) controls.
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Table 7. Loading concentrations of membranes used to test synergy of bupivacaine and C2DA
analog against P. aeruginosa.
Group
Bupivacaine
concentration
(μg/ml)
C2DA analog
concentration
(μg/ml)

1

2

500

500 1000 1000 2000

2000

250

250

0

3

4

0

250

5

6

0

Positive
control

Negative
control

TSB with no
added bacteria

P. aeruginosa +
ethanol

Results
Results of synergy studies indicate that combining the C2DA analog with bupivacaine increased
antimicrobial efficacy over either treatment alone against P. aeruginosa (Figure 17). There was
significantly less bacterial growth in wells containing bupivacaine combined with the C2DA

Relative bacteria viability

analog compared to bupivacaine only at the 0.5 mg/ml concentration.
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Figure 17. Growth of P. aeruginosa after 24 hours in trypticase soy broth with added
bupivacaine with and without C2DA analog at 250 µg/ml. Asterisk indicates significant
difference (p<0.05) between groups determined by Kruskal-Wallis ANOVA with Tukey
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Conclusions
While these studies were informative as initial indicators of anti-biofilm potential and
synergy, they were not directly applicable to the direct results of this study as they were not used
within the context of the membranes. However, understanding the baseline antimicrobial
characteristics of these therapeutics was beneficial in determining whether local anesthetics and
diffusible signal factors are functional in combination, and ensuring that they do not act
antagonistically. Further, while P. aeruginosa behaves differently than S. aureus, these
preliminary studies informed later decisions in combining therapeutics to test against other
strains. Future studies related to this test may investigate a broader range of therapeutic
concentrations against other bacterial strains.
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APPENDIX C
Biofilm Studies with P. aeruginosa
Rationale & Methods
Before conducting experiments with S. aureus, effectiveness of eluted membranes against
P. aeruginosa was investigated. C2DA is known to be effective in dispersing P. aeruginosa, so
tests were performed to ensure that enough therapeutics were released to prevent biofilm growth
of this species. First, membranes were loaded with either 25 μg of C2DA, 10 mg of bupivacaine,
or a combination of both, and were placed in phosphate buffered saline to release therapeutics for
72 hours. After the elution study, membranes were placed in 48 well plates and inoculated with a
0.5 mL solution of 106 colony forming units (CFU) of P. aeruginosa in tryptic soy broth (TSB).
After incubating at 37 °C for 24 hours, membranes were removed from wells, rinsed twice with
sterile PBS, and sonicated for 5 minutes at 40 kHz (Fisher Scientific Ultrasonic Bath, 9.5 L) to
remove biofilm-associated bacteria. PrestoBlue™ viability reagent was used to compare viable
bacteria attached to each membrane type. Briefly, the PrestoBlue™ reagent interacts with the
reducing environment associated with viable bacterial cells and produces fluorescence directly
proportional to the number of viable cells present in each well. Fluorescence was read with a
Biotek Synergy™ H1 microplate reader.
Results
Even after the majority of bupivacaine and C2DA were released from the membranes
during the 72-hour elution study, biofilm formation was significantly lower for each membrane
group (C2DA only, bupivacaine only, and C2DA combined with bupivacaine) as compared to
non-loaded (Figure 18).
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Figure 18. Biofilm on membranes after 72-hour elution. P. aeruginosa biofilm on membranes
loaded with bupivacaine, C2DA, or a combination of both, after 72 hours of elution. Bars
represent average fluorescence of PrestoBlue™ Viability reagent of bacteria removed by
sonication from membranes 24 hours after bacterial challenge. Asterisks indicate significant
difference (p<0.05) between groups and non-loaded membrane control determined by ANOVA
with Holm-Šídák post-hoc tests.
Conclusion
These results provided a preliminary understanding of interactions between C2DA and
bupivacaine. Because these membranes were tested with gram-negative P. aeruginosa, they were
not included with proceeding tests using gram-positive S. aureus. This data informs future
studies that will include other gram-negative bacterial strains, and supports the hypothesis that
membranes loaded with C2DA and bupivacaine will be effective in preventing gram-positive,
gram-negative, and potentially polymicrobial biofilm.
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